China Medical System Holdings Limited (0867.HK)
- Previous Close
7.060 - Open
7.050 - Bid 7.000 x --
- Ask 7.010 x --
- Day's Range
6.850 - 7.070 - 52 Week Range
6.850 - 15.860 - Volume
14,261,051 - Avg. Volume
6,976,035 - Market Cap (intraday)
17.084B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
6.60 - EPS (TTM)
1.060 - Earnings Date Mar 27, 2024
- Forward Dividend & Yield 0.43 (6.06%)
- Ex-Dividend Date May 13, 2024
- 1y Target Est
13.22
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. In addition, it provides Aethoxysklerol for sclerotherapy of different varicose veins; Heling Soothing product for skin soothing; Vmonalisa for mid to deep dermal implantation; Neauvia Hyaluronic Acid series; EyeOP1 to treat glaucoma; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; MOVICOL for treating chronic constipation and faecal impaction; and MeteoSpasmyl to treat gastrointestinal flatulence and pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
web.cms.net.cn/zh/home/5,701
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0867.HK
Performance Overview: 0867.HK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0867.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0867.HK
Valuation Measures
Market Cap
17.23B
Enterprise Value
11.99B
Trailing P/E
6.66
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.00
Price/Book (mrq)
1.03
Enterprise Value/Revenue
1.50
Enterprise Value/EBITDA
3.81
Financial Highlights
Profitability and Income Statement
Profit Margin
29.96%
Return on Assets (ttm)
9.56%
Return on Equity (ttm)
15.74%
Revenue (ttm)
8.01B
Net Income Avi to Common (ttm)
2.4B
Diluted EPS (ttm)
1.060
Balance Sheet and Cash Flow
Total Cash (mrq)
6.14B
Total Debt/Equity (mrq)
8.37%
Levered Free Cash Flow (ttm)
1.57B